{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:41:41Z","timestamp":1777927301465,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["Invest-Initiated Studies Program (MISP) 57180"],"award-info":[{"award-number":["Invest-Initiated Studies Program (MISP) 57180"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>The use of two potent, well-tolerated, drugs could permit the maintenance of virologic suppression even in heavily pretreated people living with HIV. In this retrospective, multicenter, simplification study (NCT03348449), we included those patients with virologic suppression who switched to raltegravir (RAL) plus boosted darunavir (b\/DRV). Overall, 345 patients (75 females, 25%) were included. Patients were largely pretreated (mean, 9.4 regimens), suppressed for a median of 41.1\u2009months. Fifty patients had \u22651 mutation against DRV. At 96\u2009weeks, the efficacy by intention-to-treat analysis (snapshot) was 73% (95%CI, 68.4\u201377.8%), but 97.1% (95%CI, 95.4\u201398.9) excluding changes due to non-virologic reasons, and virologic failure was rare (0.9%; 95%CI, 0.1\u20131.2%). Median CD4\/CD8 ratio increased from 0.59 to 0.62 (p\u2009&lt;\u20090.01), CD4+ cell count by +90\u2009cells\/\u00b5l (p\u2009&lt;\u20090.01), and mean estimated glomerular filtration rate (eGFR) increased from 85.2 to 88.5\u2009ml\/min at 96\u2009weeks, greater for patients receiving tenofovir disoproxil fumarate (eGFR, +3.6\u2009ml\/min, p\u2009=\u20090.04; serum phosphate +0.33\u2009mg\/dl; p\u2009&lt;\u20090.01). There was a continued and significant improvement in the total cholesterol\/high-density lipoprotein-cholesterol ratio. In conclusion, the simplification to a dual regimen with the combination of RAL and b\/DRV is associated with maintenance of virologic suppression, even in largely pretreated patients, with improvements in CD4+ cell count, CD4\/CD8 ratio, and in renal and lipid parameters.<\/jats:p>","DOI":"10.1177\/0956462419896478","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:15:33Z","timestamp":1583453733000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-8591","authenticated-orcid":false,"given":"Jos\u00e9 L","family":"Casado","sequence":"first","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Vizcarra","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Montejano","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Negredo","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Montero","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Mena","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario de A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Palacios","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C","family":"Lopez","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Vergas","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J","family":"Galindo","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Cabello","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jimenez Diaz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Garc\u00eda","family":"Deltoro","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Valencia, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Diaz De Santiago","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the BIRDi study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"bibr1-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cae9c"},{"key":"bibr2-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1086\/630210"},{"key":"bibr3-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903176446"},{"key":"bibr4-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61170-3"},{"key":"bibr5-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2015.1122874"},{"key":"bibr6-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1018-z"},{"key":"bibr7-0956462419896478","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"bibr8-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.006"},{"key":"bibr9-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"bibr10-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23375-6"},{"key":"bibr11-0956462419896478","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0949"},{"key":"bibr12-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181b17f53"},{"key":"bibr13-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000986"},{"key":"bibr14-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"bibr15-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004078"},{"key":"bibr16-0956462419896478","doi-asserted-by":"crossref","unstructured":"Llibre JM, Hung CC, Brinson C, et\u00a0al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.\n                      Lancet\n                      2018; 391: 839-849.","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"bibr17-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003108"},{"key":"bibr18-0956462419896478","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1046-2"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462419896478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462419896478","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462419896478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:40:17Z","timestamp":1777675217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462419896478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1177\/0956462419896478"],"URL":"https:\/\/doi.org\/10.1177\/0956462419896478","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}